PALI – palisade bio, inc. (US:NASDAQ)
Stock Stats
News
Palisade Bio Announces Participation in Two Upcoming Investor Conferences
Palisade Bio (PALI) is now covered by Stifel Nicolaus. They set a "buy" rating and a $5.00 price target on the stock.
Palisade Bio Reports Rapid Clinical, Histologic and New Mechanistic Colon Tissue RNA Sequencing Data Supporting Targeted Activity of PALI-2108 at ECCO 2026
Palisade Bio Appoints Global IBD Precision Medicine Leader Bram Verstockt, MD, PhD to Clinical Advisory Board
Palisade Bio to Participate in the Piper Sandler Virtual Novel Targets in Immunology Symposium [Yahoo! Finance]
Form SCHEDULE 13G/A PALISADE BIO, INC. Filed by: RA CAPITAL MANAGEMENT, L.P.
Form SCHEDULE 13G/A PALISADE BIO, INC. Filed by: Point72 Asset Management, L.P.
Form SCHEDULE 13G/A PALISADE BIO, INC. Filed by: PERCEPTIVE ADVISORS LLC
Form SCHEDULE 13G/A PALISADE BIO, INC. Filed by: Squadron Capital Management LLC
Form 4 PALISADE BIO, INC. For: Feb 11 Filed by: Jones Mitchell Lawrence
Top News Gainers
Top News Decliners
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.